Community-driven development of a modified progression-free survival ratio for precision oncology.

Andreas MockChristoph E HeiligSimon KreutzfeldtDaniel HuebschmannChristoph HeiningEvelin SchröckBenedikt BrorsAlbrecht StenzingerDirk JägerRichard SchlenkHanno GlimmStefan FröhlingPeter Horaknull null

Published in: ESMO open (2019)

The modified PFS ratio may represent a meaningful clinical endpoint that could aid in the design and interpretation of future precision oncology trials.

Keyphrases

free survival
palliative care
healthcare
mental health
current status